Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027651 (
tumor
)
685,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A randomized study of anticancer chemotherapy, CDDP plus ADM with/without
VCR
on patients with NSCLC was carried out. Forty-six patients received injections of CDDP (75 mg/m2) and ADM (50 mg/m2) every 4 weeks (Regimen A); 39 patients were injected with the same doses of CDDP and ADM, plus
VCR
(1.4 mg/m2, on day 1 and 0.7 mg/m2, on day 7), every 4 weeks (Regimen B). Seven patients (15%) and 10 patients (26%) achieved a partial response by Regimens A and B, respectively. The median survival time (MST) was 8.5 months in each group. Survival time of the responders (MST; 27 months) was much more prolonged than that of the non-responders (MST; 7 months) (p less than 0.01). Both regimens were well tolerated with only moderate gastrointestinal symptoms and mild bone marrow toxicities. Although the addition of
VCR
to CDDP plus ADR in NSCLC fulfilled the objective
tumor
regression, no additive effect could be obtained with regard to survival.
...
PMID:[Randomized study of cisplatin and doxorubicin with or without vincristine in non-small cell lung cancer]. 371 56
A case of leiomyosarcoma of the urinary bladder in a 33-year-old female is reported. She was admitted with the complaint of gross hematuria. Cystoscopic examination showed a thumb-tip sized mass, located at the dome. CT showed a wide-based
tumor
at the dome (CT number was 60.2 H.U.). Segmental resection of bladder was performed, followed by radiation and chemotherapy (
VCR
, ACT-D, CPM and ADM). She is alive without evidence of disease 13 months after surgery. A case report and review of the literature are presented.
...
PMID:[A case of leiomyosarcoma of the urinary bladder]. 372 34
The 6-day subrenal capsule assay was used to determine chemotherapeutic sensitivities of brain tumors. Twenty-nine brain tumors were obtained at the time of surgical resection. A minced
tumor
fragment (1-mm cube) was implanted under the renal capsule of 5- to 8- week-old normal female ddY mice. Each fragment was measured at two diameters using ocular micrometer unit (10 omu = 1.0 mm). The animals were randomized, usually 5 to 7 per group, and treated with anticancer drugs on day 1 through 5. On day 6, the mice were killed. The kidney was exteriorized and the
tumor
was again measured. The change in
tumor
size was obtained for each animal by ratio of the final
tumor
size/the initial
tumor
size. Sensitivities of tumors to anticancer agents were determined by comparing differences in mean values of the change in
tumor
size between control and treated group. Twenty-seven out of 29 specimens (93%) were submitted to evaluable assay. The response rate of 11 malignant gliomas (grade 3 and 4) was 44% and that to anticancer drugs tested were as follow: 5-FU 78%, ACNU and CPA 50%,
VCR
40%, CDDP 36%. The response rate of 3 medulloblastomas was 36%: MTX 67%, CPA 50%, ACNU and CDDP 33%. That of two low-grade gliomas (grade 2) was 29%, while that of 4 malignant brain tumors (2 metastasis, chordoma, malignant fibrous histiocytoma) was 60%. Four neurinomas and 3 meningiomas were not sensitive to Tamoxifen and none were determined for estrogen receptor. In histological analysis, the transplanted
tumor
retained similar characteristics to the original
tumor
in the cases of neurinomas, meningiomas and some gliomas. Lymphocytic infiltration was observed in many cases. In the cases of metastasis (adenocarcinomas), considerable mesenchymation and lymphocytic infiltration was observed,
tumor
cells were reduced in number with poor preservation. Clinical response in 9 cases treated with sensitive drugs were 1 complete response, 2 partial response, 5 stable and 1 progressive disease in CT examination. The subrenal capsule assay is therefore considered to be very useful for determining suitable chemotherapeutic agents for brain tumors.
...
PMID:[Responsiveness of brain tumors to chemotherapeutic agents in the subrenal capsule assay]. 372 48
Echinosporin isolated from a Streptomyces culture showed antitumor activity against rodent
tumor
models such as leukemia P388, P388/
VCR
, and fibrosarcoma Meth 1. It was marginally active against melanoma B16 and sarcoma 180. It was not active against Lewis lung carcinoma and xenograft MX-1. It inhibited the colony formation of HeLa S3 cells with a wide shoulder at low dose ranges. DNA, RNA, and protein synthesis were inhibited by echinosporin. It depressed WBC with nadir on day 3, but the recovery to the normal level after echinosporin injection was more rapid than that after mitomycin C.
...
PMID:Antitumor activity of echinosporin. 400 42
It has been suggested that flow cytometric analysis may offer an ability to select drugs for chemotherapy of malignant neoplasms. For this purpose perturbation of cell cycle travers which induced by several anti-cancer drugs were studied to determine the fundamental factors to evaluate the effectiveness of therapy for individual tumors. From these results, we have made a presumption that for the majority drugs studied, the perturbation of cell cycle travers will be proportional to
tumor
cell kill. Primary cultured cells from the human brain tumor were used to determine the effectiveness of drugs for its treatment using Factor B (the accumulated cells in SG2M phases after anti-cancer drug treatment as the percentage of cells that was previously in SG2M phases) in comparison with the results (dose-response curves) obtained by glioma cell line. The clinical application was tried using these results. A case with malignant astrocytoma had shown 20.8% for ACNU treatment, however, 85.7% for
VCR
treatment in maximum range of Factor B on the samples of the removed
tumor
at the operation (cultured cells). This patient was already treated with radiation, ACNU and other anti-cancer drugs but subsequently failed and revealed constant growth in
tumor
size. Thereafter patient was treated with
VCR
according to flow cytometric indication, there was a response, that was the first time after the desperate trials of various drugs. It was only one case, nevertheless, this result illustrates the type of studies for our plan to pursue in order to determine if flow cytometric analysis aids in the brain tumor chemotherapy by individualizing patient's treatment in near future.
...
PMID:[Application of flow cytometry to chemotherapy of malignant brain tumor]. 619 9
A total of 24 patients with urothelial cancer were treated with a combination chemotherapy consisting of vincristine (1 mg, i.v., day 1), bleomycin (15 mg, or peplomycin, 10 mg, i.m. day 2), mitomycin-C (4 mg, i.v. day 3), tegafur (600-750 mg, p.o., every day) and OK-432 (2-4 KE, i.m., day 1, 3, 5). This one-week course was repeated for an average of 4.6 courses. Of these cases, 13 patients with early stage treated as adjuvant chemotherapy after radical operation showed strong suppressive effects against
tumor
recurrence or metastasis except 3 cases. However, in advanced cancer this regimen was less effective. Therefore, we modified this regimen:
VCR
2mg and PEP, 10 mg on days 2, 4 and 6. This modified regimen was given to two patients and one showed partial response and I-A according to Karnofsky's criteria. Mild side effects such as slight leukopenia, fever up, gastrointestinal symptoms or alopecia were observed. These results suggest that this regimen could be used as an adjuvant chemotherapy after radical operation of urothelial malignancy for the purpose of protecting
tumor
recurrence or metastasis.
...
PMID:[Chemotherapy of urothelial cancer with vincristine, mitomycin C, bleomycin, tegafur and OK-432]. 620 77
Comparative studies of alternating non-cross resistant chemotherapy, A.V.N.-D.V.C. (ACNU +
VCR
+ PCZ-ADM +
VCR
+ CPA) was carried out on 19 patients with small cell lung cancer. A.V.N. (A. V.F.) therapy on 45 patients and D.V.C. therapy on 19 patients were used as historical control, respectively. A.V.N. (A.V.F.) therapy was composed of ACNU (2.5 mg/kg, day 1),
VCR
(0.02 mg/kg, once every week) and PCZ (1 mg/kg, daily) (or FT-207 (15 mg/kg, daily], and duration of one course was 6 to 8 weeks. D.V.C. therapy was composed of ADM (1 mg/kg, day 1)
VCR
(0.02 mg/kg, days 1 and 5) and CPA (2 mg/kg, days 1 to 5), and repeated every 4 weeks. A.V.N.-D.V.C. therapy was done by a timely alternation of one course of A.V.N. and two course of D.V.C. Reduction rate of
tumor
size was 84% in A.V.N.-D.V.C. therapy, 62% in A.V.N. (A.V.F.) therapy and 26% in D.V.C. therapy, respectively. Median survival time was 13 months on A.V.N.-D.N.C. therapy, 8.5 months and A.V.N. (A. V.F.) therapy and 4 months on D.V.C. therapy. Significant prolongation of median survival time was obtained in A.V.N.-D.V.C. therapy in comparison with that of historical controls. Major toxicity in A.V.N.-D.V.C. therapy was slight bone marrow suppression.
...
PMID:[Combination chemotherapy for small cell carcinoma of the lung: AVN-DVC therapy]. 632 83
Three patients with malignant gliomas were treated with the high-dose chemotherapy with autologous bone marrow transplantation. In the first two cases, the autologous bone marrow cells were stored and transplanted 48 hours after single high-dose of ACNU therapy. (800 mg/m2, 600 mg/m2) One died of intratumorous bleeding on the 18th day and the other of pulmonary fibrosis on the 35th day. Their autopsy specimens revealed that most of the
tumor
had degenerated with only a small portion of viable cells. The third patient was treated with high-doses of ADM (100 mg/m2),
VCR
(1.5 mg/m2), DDP (80 mg/m2), and EX (800 mg/m2) within eight days, prior to the cryopreserved bone marrow transplantation. Granulocytes and platelets began to increase from ten days after the transplantation and became normalized within three weeks thereafter. CT scan performed six months after the chemotherapy revealed 89% reduction of the
tumor
. The number of our cases is still small, but the results showed that the autologous bone marrow transplantation made high-dose chemotherapy possible. The necessity for cryopreservation of bone marrow was discussed.
...
PMID:[High-dose chemotherapy with autologous bone marrow transplantation for malignant brain tumors]. 635 61
The results obtained using a rapid assay for in vitro chemosensitivity detection of leukemias are presented. The assay, performed according to the technique already described, involves in vitro incubation of a
tumor
cell suspension with various concentrations of antitumor drugs for 1 h and evaluation of drug-induced cell damage by addition to the cultured cells of 125I-deoxyuridine 48 h after pharmacological treatment. Results are expressed as percent inhibition of the isotope incorporation with respect to untreated controls. Preliminary results demonstrated that this assay is able to evidence differential chemosensitivity exhibited in vivo by murine leukemias. The present study reports the results obtained using comparatively P388 and P388/ADR, a subline of P388 murine leukemia with acquired resistance to Adriamycin in vivo. We found that P388/ADR exhibited resistance to ADR and DNR at all the concentrations tested, whereas P388 was highly sensitive. Cross-resistance of P388/ADR was also found to some structurally dissimilar agents, i.e.
VCR
and Act-D. These in vitro results correlate well with much data in the literature concerning the characteristics of resistance and cross-resistance exhibited in vivo by P388/ADR. These results suggest the possibility of using a similar in vitro assay for predicting the in vivo drug resistance of human leukemias.
...
PMID:[In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin]. 647 49
Two kinds of, serially transplantable human
tumor
cell lines were established in nude mice in ascitic form. One is breast cancer cell line, poorly differentiated adenocarcinoma, Hattori strain, and the other is acute lymphocytic leukemia cell line, T-cell type, Ichikawa strain. There exists a distinct correlation between the survival time of nude mice and the number of
tumor
cells transplanted. Clinically established antitumor agents which showed over 200% increase in life span were MMC, ADM and 5FU in Hattori strain, and
VCR
, VLB, VDS, ADM and BH-AC in Ichikawa strain. These results were considered to be consistent with the clinical effect of these drugs in breast cancer or in acute lymphocytic leukemia. Both strains can serve as the reliable screening system of antitumor agents.
...
PMID:[Screening test of antitumor agents by human tumor cell lines in nude mice in ascitic form]. 659 Aug 78
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>